ライフサイエンスコーパス: osteoprotegerin

1 ngiogenesis, which was completely blocked by osteoprotegerin.

2 sible using antibodies to RANKL or synthetic osteoprotegerin.

3 ifically blocked by the RANKL decoy receptor osteoprotegerin.

4 decreased expression of RANKL and increased osteoprotegerin.

5 ) that could be blocked by pretreatment with osteoprotegerin.

6 shed expression of the RANKL decoy receptor, osteoprotegerin.

7 P, fibrinogen, sICAM-1, sTNFRI, sTNFRII, and osteoprotegerin.

8 ing factor-1, and decrease the expression of osteoprotegerin.

9 by concurrent treatment with ibandronate or osteoprotegerin.

10 K on osteoclast surfaces by RANKL similar to osteoprotegerin.

11 colony-stimulating factor, RANK ligand, and osteoprotegerin.

12 to that of its physiological decoy receptor osteoprotegerin.

13 asma levels of osteopontin, osteocalcin, and osteoprotegerin (204%, 148%, and 55%, respectively; P <

14 epressed osteoclast progenitor expression of osteoprotegerin, a decoy receptor for RANKL previously t

15 EAK- or RANKL-neutralizing antibodies and by osteoprotegerin, a decoy receptor for RANKL.

16 This effect was inhibited by osteoprotegerin, a decoy receptor for receptor activator

17 proteins regulates osteoblast expression of Osteoprotegerin, a major inhibitor of osteoclast differe

18 e of the genes identified in this screen was osteoprotegerin, a member of the tumor necrosis factor r

19 Administration of osteoprotegerin, a naturally secreted decoy receptor tha

20 Here we show that osteoprotegerin, a secreted 'decoy' receptor that inhibi

21 Targeting the RANKL pathway by osteoprotegerin administration abrogated periodontal bon

22 king finding was the significant decrease in osteoprotegerin, an osteoclastogenesis inhibitory factor

23 up EP-HN019 presented greater expressions of osteoprotegerin and beta-defensins than group EP (P <0.0

24 vels of biomarkers of vascular inflammation (osteoprotegerin and C-terminal proendothelin-1, adjusted

25 Deletion of Cnb1 increased expression of osteoprotegerin and decreased expression of RANKL.

26 al fibroblasts, increasing the expression of osteoprotegerin and decreasing receptor activator of nuc

27 ow that muscle cells can produce and secrete osteoprotegerin and pharmacologic treatment of dystrophi

28 We found that serum levels of osteoprotegerin and soluble osteoclast differentiation f

29 cently been identified: the secreted protein osteoprotegerin and the cell-surface ligand to which it

30 ys a unique role in osteocytes, up-regulates osteoprotegerin and Wnt signaling, and differentially re

31 -polymerase chain reaction (RT-PCR) for OPG (osteoprotegerin); and RANKL (receptor activator of NF-ka

32 Some of these, including oxidized lipids, osteoprotegerin, and bisphosphonates, appear to regulate

33 rcarboxylated osteocalcin (%ucOC)] and IL-6, osteoprotegerin, and C-reactive protein (CRP) concentrat

34 Concentrations of IL-6, osteoprotegerin, and CRP and bone mineral density (BMD)

35 ces were observed in the 3-y change in IL-6, osteoprotegerin, and CRP concentrations between particip

36 ion regulators bone morphogenetic protein 2, osteoprotegerin, and interleukin 6.

37 g regulators of vascular calcification (OPN, osteoprotegerin, and leptin), PTH(1-34) regulated only s

38 lis infection, while mRNA for interleukin-1, osteoprotegerin, and STAT6 all increased in the suscepti

39 -H+-ATPase inhibitor SB 242784, the cytokine osteoprotegerin, and the amino bisphosphonates alendrona

40 tivator of nuclear factor-kappaB ligand, and osteoprotegerin; and up-regulate osteoclast formation.

41 igand (RANKL) and variable downregulation of osteoprotegerin are implicated, and bone health may impr

42 aB ligand (RANKL) and its receptors RANK and osteoprotegerin are key regulators of bone remodeling bu

43 e investigated whether circulating levels of osteoprotegerin are related to features of CMV disease a

44 ligand RANKL, and the soluble decoy receptor osteoprotegerin are the key regulators of osteoclast dif

45 Our data identify osteoprotegerin as a novel protector of muscle integrity

46 ctivator of NF kappa B ligand and suppresses osteoprotegerin at concentrations two logs lower than th

47 h the receptor activator of NF-kappaB ligand/osteoprotegerin axis was unaffected, expression of tumor

48 of a distinct program of genes that included osteoprotegerin, BCL-2, and IAP-1 (inhibitor of apoptosi

49 Knock-down of the expression of osteoprotegerin, BCL-2, or inhibitor of apoptosis protei

50 pression of osteoblast alkaline phosphatase, osteoprotegerin, collagen, and Runx2.

51 vary biomarkers (especially MMP-8 and -9 and osteoprotegerin) combined with red-complex anaerobic per

52 nuclear factor-kappaB ligand and decrease in osteoprotegerin, compared to WTI mice.

53 The association observed between increased osteoprotegerin concentrations and periodontitis was los

54 Salivary osteoprotegerin concentrations were higher in the GP and

55 A truncate of osteoprotegerin, containing the ligand-binding domains b

56 appaB ligand (RANKL) coupled with decline in osteoprotegerin correlate with decreased bone mineral de

57 , whereas decoy receptor 1 (DcR1), DcR2, and osteoprotegerin counteract this function.

58 Juvenile Paget's disease can result from osteoprotegerin deficiency caused by homozygous deletion

59 Osteoprotegerin deficiency could explain juvenile Paget'

60 However, a neutralizing antibody to osteoprotegerin did not rescue reduced OCL formation in

61 Suppression of osteoclast formation with osteoprotegerin dose-dependently inhibited angiogenesis

62 nate zoledronic acid and the RANKL inhibitor osteoprotegerin, each blocked GM-CSF-induced tumor growt

63 of the osteoclastogenesis inhibitory factor osteoprotegerin enabled early growth of SS18-SSX2-transf

64 hematical model based on type I collagen and osteoprotegerin expression that predicts the bone-formin

65 aB ligand (RANKL) production, an increase in osteoprotegerin expression, and a decrease in serum tart

66 ANKL and M-CSF, saturating concentrations of osteoprotegerin failed to inhibit approximately 40% of t

67 nic diet-fed ldlr(-/-) mice with recombinant osteoprotegerin (Fc-OPG) or vehicle for 5 months.

68 o-color flow cytometry using FITC-conjugated osteoprotegerin-Fc (OPG-Fc-FITC) as a probe.

69 AT/enhancer-binding protein-beta and -delta, osteoprotegerin, FOXC2 and FOXF2, BMP-2, p75 neurotrophi

70 eceived an injection of anti-RANKL antibody, osteoprotegerin fusion protein (OPG-Fc), or a control fu

71 This effect was antagonized by injection of osteoprotegerin fusion protein into the local gingival t

72 by incubation with the RANKL decoy receptor osteoprotegerin fusion protein.

73 showed that Smad1 activates osteopontin and osteoprotegerin gene expression by dislodging Hoxc-8 fro

74 801, on chromosome 8, near to the TNFRSF11B (osteoprotegerin) gene, and rs3736228, on chromosome 11 i

75 The ligand for osteoprotegerin has been identified, and it is a TNF-rel

76 The newly described agent osteoprotegerin has been shown in early studies to inhib

77 blocked by treatment with human recombinant osteoprotegerin (hrOPG).

78 ppa B ligand at day 7 post-treatment, strong osteoprotegerin immunoreactivity was observed at day 15

79 by NF-kappaB and indicate a new function for osteoprotegerin in endothelial cells.

80 shed novel roles for tumor-derived CCL20 and osteoprotegerin in inducing CCL2 production from macroph

81 one marrow fibrosis and stromal cell-derived osteoprotegerin in promoting osteosclerosis.

82 ace membrane fibroblasts expressed RANKL and osteoprotegerin in response to stimulation with conditio

83 These data support a role for osteoprotegerin in the vasculature as an inhibitor of ca

84 The role of osteoprotegerin in vascular disease is unclear.

85 turnover, including interleukin-6 (IL-6) and osteoprotegerin in vitro.

86 conjunction with their shared decoy receptor osteoprotegerin, in the bone marrow of infected IFrag(-/

87 To test whether osteoprotegerin induces or prevents vascular disease, we

88 (3)-mediated endothelial survival depends on osteoprotegerin induction by NF-kappaB and indicate a ne

89 Osteoprotegerin induction by osteopontin was time-depend

90 or in endothelial cells completely inhibited osteoprotegerin induction by osteopontin.

91 Osteoprotegerin is a marker of vascular and systemic inf

92 on SLA and modSLA [e.g., prostaglandin E(2), osteoprotegerin, latent and active TGF-beta1, and stimul

93 osis factor (TNF)-alpha, C-reactive protein, osteoprotegerin, leptin, and adiponectin were determined

94 , a calcium-sensing receptor related factor, osteoprotegerin, leptin, bisphosphonates and oxidized li

95 Recent observational studies show that serum osteoprotegerin levels are associated with the severity

96 Our finding indicates that elevated osteoprotegerin levels in solid organ transplant recipie

97 essive atherosclerosis with increased plasma osteoprotegerin levels, consistent with observational st

98 Osteoprotegerin Ligand (OPGL) is a member of the tumor n

99 Osteoprotegerin ligand (OPGL) targets osteoclast precurs

100 ivator of NF-kappaB (RANK), the receptor for osteoprotegerin ligand (OPGL), also known as RANK ligand

101 tem is enhanced by the addition of exogenous osteoprotegerin ligand (OPGL), an essential Ocl differen

102 A receptor that mediates osteoprotegerin ligand (OPGL)-induced osteoclast differe

103 insic cell surface determinant that mediates osteoprotegerin ligand effects on bone resorption and re

104 nduced cytokine (TRANCE, also referred to as osteoprotegerin ligand), and kit ligand-1 (KL-1) in vitr

105 enetic interactions between osteoprotegerin, osteoprotegerin ligand, and RANK during bone resorption

106 t differentiation factor (ODF; also known as osteoprotegerin ligand, receptor activator of nuclear fa

107 01 with Bonferroni correction for both), but osteoprotegerin lost significance after age and sex adju

108 differentiation and calcification inhibitors osteoprotegerin, matrix Gla protein, and osteopontin.

109 c and treatment studies in mice suggest that osteoprotegerin may protect against vascular calcificati

110 the generation of bone cancer pain and that osteoprotegerin may provide an effective treatment for t

111 of soluble RANKL, but not its decoy receptor osteoprotegerin, measured in diseased tissue homogenates

112 ding macrophage inflammatory protein-1Delta, osteoprotegerin, monokine induced by interferon-gamma (I

113 In contrast, osteoprotegerin mRNA and protein levels were induced 5-7

114 By Northern and Western blot analysis, osteoprotegerin mRNA and protein levels were very low in

115 ndent osteoclastic activity due to decreased osteoprotegerin mRNA expression in these cells.

116 3, macrophage colony-stimulating factor, and osteoprotegerin mRNA expression.

117 Inhibition of osteoprotegerin mRNA in WT cells was partial with either

118 Vit D decreased osteoprotegerin mRNA to undetectable in all groups.

119 Osteoprotegerin mRNA was increased, sclerostin and dickk

120 hosphatase mRNA levels, and potently induced osteoprotegerin mRNA, whereas LiCl was ineffective alone

121 tin but decreased expression of osteocalcin, osteoprotegerin (mRNA and protein), and smad2.

122 Tumor necrosis factor and osteoprotegerin mRNAs are more highly expressed in the g

123 ment of dystrophic mdx mice with recombinant osteoprotegerin muscles.

124 TNF-related apoptosis-inducing ligand; OPG, osteoprotegerin; Omp29, 29-kDa outer membrane protein; P

125 r of nuclear factor kappaBeta ligand (RANKL)/osteoprotegerin (OPG) (2.5 +/- 0.7-fold, p < 0.001) rati

126 Both osteoprotegerin (OPG) and anti-TNF antibodies inhibited

127 Osteoprotegerin (OPG) and OPG-ligand (OPGL) potently inh

128 Osteoprotegerin (OPG) and receptor activator of nuclear

129 KL) mRNA, whereas ES increased expression of osteoprotegerin (OPG) and the OPG/RANKL ratio.

130 o compare the activity of TSG-6 with that of osteoprotegerin (OPG) and to investigate its role as an

131 r activator of NF-kappaB) and decoy receptor osteoprotegerin (OPG) are constitutively expressed at al

132 tor for NF-kappaB (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG) axis and expression of the transcr

133 ar factor-kappa B (RANK)-RANK ligand (RANKL)-osteoprotegerin (OPG) axis.

134 L-6) in iDCs and also increased secretion of osteoprotegerin (OPG) by DCs.

135 nic markers, alkaline phosphatase (ALP), and osteoprotegerin (OPG) by hMSCs and transcriptome analysi

136 ulatory factors in osteoblasts by decreasing osteoprotegerin (OPG) expression and increasing monocyte

137 ld lower RANKL expression but >2-fold higher osteoprotegerin (OPG) expression than donor-matched ABCs

138 ormone-related protein (PTHrP) down-regulate osteoprotegerin (OPG) gene expression in the dental foll

139 of nuclear factor kappa B ligand (RANKL) and osteoprotegerin (OPG) immunohistochemistry was carried o

140 IL-6, IL-8, tumor necrosis factor-alpha, and osteoprotegerin (OPG) in HGF and HPLF.

141 High systemic levels of osteoprotegerin (OPG) in OPG transgenic mice cause osteo

142 from tumor cells suppress the expression of osteoprotegerin (OPG) in osteoblasts and subsequently po

143 s and indirectly by increasing expression of osteoprotegerin (Opg) in osteoblasts.

144 bular molar, a decrease in the expression of osteoprotegerin (OPG) in the dental follicle at day 3 en

145 ukin (IL)-17A, IL-17E, IL-17F, IL-17A/F, and osteoprotegerin (OPG) in women with rheumatoid arthritis

146 lear factor-kappa B ligand (RANKL) inhibitor osteoprotegerin (OPG) inhibits osteoclastogenesis and su

147 Osteoprotegerin (OPG) inhibits RANK signaling by sequest

148 The secreted, soluble receptor osteoprotegerin (OPG) interrupts this activation by bind

149 Osteoprotegerin (OPG) is a CD40-regulated gene in B cell

150 Osteoprotegerin (OPG) is a decoy receptor for tumor necr

151 Osteoprotegerin (OPG) is a glycoprotein that acts as a d

152 Osteoprotegerin (OPG) is a key regulator of bone remodel

153 Osteoprotegerin (OPG) is a marker and regulator of arter

154 Osteoprotegerin (OPG) is a member of the tumor necrosis

155 Osteoprotegerin (OPG) is a secreted protein that inhibit

156 Osteoprotegerin (OPG) is a soluble nonsignaling receptor

157 Osteoprotegerin (OPG) is an osteoblast-secreted glycopro

158 The secreted glycoprotein osteoprotegerin (OPG) is emerging as an important regula

159 Osteoprotegerin (OPG) is involved in bone homeostasis an

160 of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin (OPG) levels and RANKL/OPG ratios in ser

161 pressed significantly higher RANKL and lower osteoprotegerin (OPG) mRNA and increased RANKL:OPG ratio

162 uclear factor kappaB ligand (RANKL) and RANK/osteoprotegerin (OPG) plays a dominant role in osteoclas

163 of nuclear factor kappaB ligand (RANKL) with osteoprotegerin (OPG) prevents the osteolytic activity o

164 or activator of NF-kappaB ligand (RANKL) and osteoprotegerin (OPG) production by ST2 cells, despite M

165 igand (RANKL) expression and down-regulating osteoprotegerin (OPG) production.

166 f nuclear factor kappaB ligand) promotes and osteoprotegerin (OPG) protects against vascular calcific

167 ce with established myeloma with recombinant osteoprotegerin (OPG) protein, the soluble decoy recepto

168 e dermatomyositis (DM), to compare the RANKL:osteoprotegerin (OPG) ratio in patients with juvenile DM

169 f nuclear factor kappa-B ligand (RANKL)-RANK-osteoprotegerin (OPG) signaling associated with bone res

170 or activator of NF-kappaB ligand (RANKL) and osteoprotegerin (OPG) signaling in osteocytes was not st

171 ctor-kappaB (RANK), RANK ligand (RANKL), and osteoprotegerin (OPG) signaling pathway (RANKL/RANK/OPG

172 r activator of NF-kappaB ligand (RANKL), and osteoprotegerin (OPG) that modulate bone homeostasis.

173 We found that the expression of osteoprotegerin (OPG) was induced by genistein and inhib

174 The gene for osteoprotegerin (OPG) was up-regulated by both parasites

175 ctor kappaB (RANK), RANK ligand (RANKL), and osteoprotegerin (OPG) were also investigated by immunohi

176 of nuclear factor-kappaB ligand (RANKL), and osteoprotegerin (OPG) were analyzed in the furcation are

177 of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin (OPG) were assessed by enzyme-linked imm

178 s, RvE1 significantly enhanced expression of osteoprotegerin (OPG) without inducing change in recepto

179 Osteoprotegerin (OPG), a critical regulator of osteoclas

180 Serum levels of osteoprotegerin (OPG), a decoy receptor for RANKL, stead

181 teoclastogenesis by inhibiting expression of osteoprotegerin (OPG), a decoy receptor for the receptor

182 Osteoprotegerin (OPG), a decoy receptor secreted by oste

183 Osteoprotegerin (OPG), a member of the tumor necrosis fa

184 Osteoprotegerin (OPG), a natural negative regulator of o

185 Osteoprotegerin (OPG), a novel, secreted tumor necrosis

186 or of nuclear factor-kappaB ligand (sRANKL), osteoprotegerin (OPG), a proliferation-inducing ligand (

187 t survival, in part through the induction of osteoprotegerin (OPG), a protein known to inhibit osteoc

188 ve identified a fifth TRAIL receptor, namely osteoprotegerin (OPG), a secreted tumor necrosis factor

189 derived receptor-1 (FDCR-1), is identical to osteoprotegerin (OPG), a soluble cytokine that regulates

190 hormones or cytokines, and is neutralized by osteoprotegerin (OPG), a soluble decoy receptor also cru

191 addition to its effects on bone metabolism, osteoprotegerin (OPG), a soluble member of the tumor nec

192 Osteoprotegerin (OPG), a soluble receptor of the cytokin

193 Osteoprotegerin (OPG), an immunoregulatory member of the

194 nd activation, we examined the expression of osteoprotegerin (OPG), an inhibitor of osteoclast format

195 imulated expression of interleukin-6 but not osteoprotegerin (OPG), an inhibitor of RANKL.

196 Osteoprotegerin (OPG), an osteoblast-secreted decoy rece

197 Interleukin (IL)-1beta, osteoprotegerin (OPG), and bone-specific alkaline phosph

198 ptor activator of NF-kappa B ligand (RANKL), osteoprotegerin (OPG), and monocyte chemotactic and stim

199 r factor-kappaB (RANK), RANK-ligand (RANKL), osteoprotegerin (OPG), and osteocalcin was performed.

200 he levels and relative ratios of sclerostin, osteoprotegerin (OPG), and receptor activator of nuclear

201 or of nuclear factor-kappa B ligand (RANKL), osteoprotegerin (OPG), and tartrate-resistant acid phosp

202 tor of nuclear factor kappaB ligand (RANKL), osteoprotegerin (OPG), and tartrate-resistant acid phosp

203 ctivator of nuclear factor-kappaB (RANK) and osteoprotegerin (OPG), are known to be regulators of dev

204 r of nuclear factor-kappa B ligand (sRANKL), osteoprotegerin (OPG), B-cell activating factor (BAFF),

205 oclast numbers and activity are regulated by osteoprotegerin (OPG), bisphosphonates suppress osteocla

206 kappaB (RANK), soluble RANK ligand (sRANKL), osteoprotegerin (OPG), cathepsin-K, and sclerostin.

207 on index (ACI), fibroblast growth factor 23, osteoprotegerin (OPG), fetuin A, and clinical and bioche

208 The protein, termed Osteoprotegerin (OPG), is a novel member of the TNF rece

209 of TRAIL, DR5 and the TRAIL decoy receptors osteoprotegerin (OPG), mDcTRAILR1, and mDcTRAILR2 were d

210 gate virus, we found that a soluble protein, osteoprotegerin (OPG), or an OPG/Fc chimeric protein inh

211 of Nuclear factor Kappa B Ligand (RANKL) and osteoprotegerin (OPG), positive and negative regulators

212 Osteoprotegerin (OPG), receptor activator of nuclear fac

213 d soluble TNF receptor type I (pegTNFRI) and osteoprotegerin (OPG), respectively, affected bony spur

214 tor of nuclear factor-kappaB ligand (RANKL), osteoprotegerin (OPG), tartrate-resistant acid phosphata

215 nce with RANKL by systemic administration of osteoprotegerin (OPG), the decoy receptor for (and inhib

216 ceptor activator of NF-kappaB ligand (RANKL)/osteoprotegerin (OPG), tumor necrosis factor alpha (TNF-

217 tor of nuclear factor-kappaB ligand (RANKL), osteoprotegerin (OPG), wingless (WNT) 10b, dickkopf-rela

218 recent work showed that daily injections of osteoprotegerin (OPG)-immunoglobulin fragment complex (O

219 predictive markers of bone inflammation-the osteoprotegerin (OPG)-RANK-RANKL system or osteopontin (

220 gand (RANKL) relative to its decoy receptor, osteoprotegerin (OPG).

221 nuclear factor-kappaBeta ligand (RANKL) and osteoprotegerin (OPG).

222 inhibited by a soluble decoy receptor called osteoprotegerin (OPG).

223 ctor-kappaB, and subsequent up-regulation of osteoprotegerin (OPG).

224 and (RANKL) and inhibiting the expression of osteoprotegerin (OPG).

225 (TRANCE) and decrease in its decoy receptor, osteoprotegerin (OPG).

226 inistration of the decoy receptor for RANKL, osteoprotegerin (OPG).

227 cross-talk through the direct regulation of osteoprotegerin (OPG).

228 factor-kappaB ligand and decreased levels of osteoprotegerin (OPG).

229 stogenesis due to insufficient production of osteoprotegerin (Opg).

230 of nuclear factor-kappa B ligand (RANKL); 2) osteoprotegerin (OPG); 3) interleukin (IL)-6; and 4) tum

231 eine chemokine receptor-5 (CCR5, 59653 C>T), osteoprotegerin (OPG, 245 T>G), and osteopontin (OPN, 70

232 mentation rate, and bone metabolism markers (osteoprotegerin [OPG], osteocalcin, procollagen type I N

233 hymic epithelial cells by using mice lacking osteoprotegerin or by adding TRANCE (RANKL, Tnfsf11).

234 this system with recombinant decoy receptor, osteoprotegerin, or soluble forms of the receptor activa

235 r for nuclear factor kappa-B ligand (RANKL), osteoprotegerin, osteocalcin, and osteopontin as potenti

236 Salivary levels of RANKL, osteoprotegerin, osteocalcin, osteopontin, and serum gly

237 steoblast markers bone alkaline phosphatase, osteoprotegerin, osteopontin, and matrix Gla protein.

238 e the molecular genetic interactions between osteoprotegerin, osteoprotegerin ligand, and RANK during

239 Targeting the RANKL/osteoprotegerin pathway may lead to therapies that impro

240 although EDNRA activation had no effects on osteoprotegerin production.

241 Finally, purified osteoprotegerin protected endothelial cells with inactiv

242 After 6 days of treatment, osteoprotegerin protein in cell supernatants was 40-fold

243 whereas no inhibition was observed by adding osteoprotegerin, RANK:Fc, TNFalpha, or interleukin-8 or

244 This is achieved by decreasing the osteoprotegerin/RANKL expression ratio.

245 ppaB ligand (RANKL)), the deviation of RANKL/osteoprotegerin ratio in favor of antiosteoclastic activ

246 duced receptor activator of NF-kappaB ligand/osteoprotegerin ratio in Runx2-overexpressing osteoblast

247 l analyses for the detection of osteocalcin, osteoprotegerin, receptor activator of nuclear factor ka

248 on-gamma, toll-like receptor (TLR)-2, TLR-4, osteoprotegerin, receptor activator of nuclear factor-ka

249 pha1, osteocalcin, alkaline phosphatase, and osteoprotegerin, representative bone-regulating proteins

250 osteoblast differentiation, also stimulates osteoprotegerin secretion to attenuate bone resorption b

251 A substantial part of the actions of osteoprotegerin seems to result from inhibition of tumor

252 This enhanced chemotaxis can be abrogated by osteoprotegerin (soluble decoy receptor of RANKL), MIK-G

253 uld explain juvenile Paget's disease because osteoprotegerin suppresses bone turnover by functioning

254 The map locations of 25 genes including osteoprotegerin, syndecan-2, and autotaxin have been ref

255 receptor activator of nuclear factor kappa B/osteoprotegerin system involved in osteoblast-osteoclast

256 Manipulation of the RANKL/osteoprotegerin system now is feasible using antibodies

257 ew, we provide an overview of the RANK/RANKL/osteoprotegerin system; we describe its interaction with

258 g proteins, like hepatocyte growth factor or osteoprotegerin, they concentrate in the uropod.

259 f receptor activator of NF-kappaB ligand and osteoprotegerin through both PTH-dependent and -independ

260 t's disease for defects in the gene encoding osteoprotegerin (TNFRSF11B) using polymerase-chain-react

261 rationally designed small molecule mimic of osteoprotegerin to inhibit osteoclast formation in vitro

262 lance stemmed from a switch in production of osteoprotegerin to that of receptor activator of NF-kapp

263 However, OC-defective osteoprotegerin transgenic (OPG(Tg)) mice and bisphospho

264 Results indicated that osteoprotegerin treatment halted further bone destructio

265 Gene expression levels of soluble RANKL, osteoprotegerin, tumor necrosis factor alpha, and M-CSF

266 ator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin, tumor necrosis factor-alpha, and interl

267 eptor-activated nuclear factor-kappaB ligand/osteoprotegerin/tumor necrosis factor-related apoptosis-

268 Osteoprotegerin was associated positively with plasma ph

269 Elevated plasma osteoprotegerin was associated with (i) certain disease

270 sitive to the effects of the RANKL inhibitor osteoprotegerin was identified in the activated T cell-c

271 steocalcin, and osteopontin were higher, and osteoprotegerin was lower in females than in males.

272 ctivator of nuclear factor-kappaB ligand and osteoprotegerin) was observed in the ligature group on d

273 Alterations in BM plasma levels of RANKL/osteoprotegerin were confirmed in a mouse model of posti

274 F-kappaB ligand (RANKL), and its antagonist, osteoprotegerin were measured.

275 scular cell adhesion molecule 1 (VCAM-1) and osteoprotegerin were significantly associated with incid

276 d macrophage inflammatory protein-1Delta and osteoprotegerin were significantly elevated in patients

277 lasma levels of RANKL and of the ratio RANKL/osteoprotegerin were significantly elevated in patients

278 Osteopontin and osteoprotegerin were significantly elevated in the sympt

279 hereas other genes, such as interleukin-5 or osteoprotegerin, were initially identified as having a r

280 or Tax and the osteoclast inhibitory factor, osteoprotegerin, were protected from osteolytic bone dis

281 Osteoprotegerin, which was expressed constitutively, was